Today, a Director at Jaguar Animal Health (JAGX), James Bochnowski, bought shares of JAGX for $361.2K.
Following this transaction James Bochnowski’s holding in the company was increased by 17430.69% to a total of $319.6K. In addition to James Bochnowski, one other JAGX executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Jaguar Animal Health’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $1.59 million and GAAP net loss of $8.3 million. In comparison, last year the company earned revenue of $883.8K and had a GAAP net loss of $7.66 million. Currently, Jaguar Animal Health has an average volume of 203.1K.
James Bochnowski’s trades have generated a -78.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments.
